Back to News
Market Impact: 0.2
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
Source: Business Wire
Patents & Intellectual PropertyHealthcare & Biotech
bioAffinity announced that it received a Hong Kong patent protecting the proprietary technology underlying its noninvasive CyPath Lung diagnostic for lung cancer. The patent strengthens intellectual-property protection in Hong Kong for the company’s diagnostic platform, but the release provides no revenue, clinical-validation, or commercialization metrics.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BIAF0.72
More News
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- Ultragenyx stock surges 10% on FDA approval for gene therapy